FOSUN WANBANG
GenericsFOSUN WANBANG is a generic drug manufacturer focused on Oncology, Gastroenterology, Cardiovascular.
FOSUN WANBANG's Key Drugs
FOSUN WANBANG's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
FOSUN WANBANG's Recent FDA Approvals
New NDA/BLA approvals for FOSUN WANBANG over the last two years — novel drugs only, excluding generics and label supplements.
FOSUN WANBANG's Therapeutic Areas
FOSUN WANBANG's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
FOSUN WANBANG's Top Competitors
FOSUN WANBANG's closest competitors by therapeutic-area and drug-target overlap include Takeda, Novartis, and Amgen. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
FOSUN WANBANG Pipeline Snapshot
Active clinical trials for FOSUN WANBANG across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2005-09-13
- Latest
- 2024-06-12
- Applications
- 4